California Resources Prices Offering of Senior Notes due 2034-March 2024-www.financetom.com

California Resources Prices Offering of Senior Notes due 2034

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

California Resources Prices Offering of Senior Notes due 2034

Mar 11, 2026 3:20 PM

05:52 PM EDT, 03/11/2026 (MT Newswires) -- California Resources ( CRC ) said late Wednesday it priced an upsized private offering of $350 million of 7% senior unsecured notes due 2034.

The offering is expected to be completed on March 23, subject to closing conditions, according to a statement.

Net proceeds will be used to redeem $350 million of its 8.25% senior unsecured notes due 2029, the company said.

Previous page： Kroger, Albertsons amend asset sale agreement with C&S Wholesale Next page： IDEAYA Biosciences Selects Move-Forward Expansion Dose for Mid-Stage Trial of IDE397 Monotherapy

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Kroger, Albertsons amend asset sale agreement with C&S Wholesale

Apr 22, 2024

(Reuters) -Kroger ( KR ) and Albertsons Cos ( ACI ) said on Monday that they have amended their definitive agreement with C&S Wholesale Grocers for the sale of assets in connection with their proposed merger. The companies have updated their divestiture package to increase the total store count by 166 to include 579 stores that will be sold to...

IDEAYA Biosciences Selects Move-Forward Expansion Dose for Mid-Stage Trial of IDE397 Monotherapy

Apr 22, 2024

08:45 AM EDT, 04/22/2024 (MT Newswires) -- IDEAYA Biosciences ( IDYA ) said Monday that it has selected a move-forward expansion dose for a mid-stage trial evaluating its IDE397 monotherapy in MTAP-deletion squamous non-small cell lung cancer, or NSCLC. Squamous NSCLC has been identified as the most sensitive tumor type of IDE397 monotherapy, the company said. There are more than...

Satellogic Commits to Backing Amazon Rainforest Monitoring Project

Apr 22, 2024

08:49 AM EDT, 04/22/2024 (MT Newswires) -- Satellogic ( SATL ) said Monday it signed a letter of intent with O.N.E. Amazon to advance conservation goals. Financial terms of the preliminary deal were not disclosed. Satellogic ( SATL ) will use its technology to power O.N.E. Amazon's project to create what it describes as an Internet of Forests, a network...

Lexeo Therapeutics Signs License Deal With Cornell for Potential Friedreich Ataxia Cardiomyopathy Drug

Apr 22, 2024

08:47 AM EDT, 04/22/2024 (MT Newswires) -- Lexeo Therapeutics ( LXEO ) said Monday that it has signed an in-license agreement with Cornell University to expedite the development of investigational gene therapy candidate LX2006 to treat Friedreich ataxia cardiomyopathy. Under the deal, Lexeo said it has acquired certain rights, including rights to current and future data generated in an ongoing...